Overview

Tau Screening Study in Subjects With Early Symptomatic AD

Status:
Completed
Trial end date:
2018-11-15
Target enrollment:
Participant gender:
Summary
This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron Emission Tomography (PET) scan.
Phase:
Phase 2
Details
Lead Sponsor:
Avid Radiopharmaceuticals